You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: L2 DIAGNOSTICS LLC Topic: NCI
DESCRIPTION (provided by applicant): Epidermal Growth Factor Receptor (EGFR) bearing tumors remain as one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing novel tumor immunotherapy by using both cryptic peptides of EGFR protein as well as isoaspartyl modified EGFR peptides, both of which brea ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: VASADE BIOSCIENCES, INC. Topic: NHLBI
DESCRIPTION (provided by applicant): 6. Abstract Almost 20 million people suffer from ischemic heart diseases in US and one million patients develop myocardial infarction (MI) every year. Many patients develop heart failure even if they survive the acute event, which clearly indicates that current interventions are not sufficient. Thus, the development of a new class of medicine, which prevents is ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: MABVAX THERAPEUTICS, INC. Topic: NCI
DESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Cetya Therapeutics, Inc. Topic: NHLBI
PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Tfc Consultants, Inc. Topic: NIMH
DESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: ZMK Medical Technologies, Inc. Topic: 102
This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Zetroz Systems LLC Topic: A14AT016
Ultrasound is a therapeutic modality which has been used clinically for 60 years, but has been limited in practice by the complexity of the technology. Recent research has allowed for the development of a portable, wearable, long duration, low intensity therapeutic ultrasound system. The system is powered by battery, and can be applied by a user to deliver upSTTR Phase II 2016 Department of DefenseDefense Health Agency
SBC: GRIFFIN LABORATORIES, INC. Topic: NIDCD
DESCRIPTION (provided by applicant): The most common artificial voice source for post-laryngectomy speech rehabilitation is the hand-held buzzer or electrolarynx (EL). This device is relatively easy to use and enables most laryngectomees to verbally communicate, but with reduced intelligibility and markedly degraded naturalness. In addition, EL speech is often described as robotic and monotone, at ...STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: ARCHIE MD INC. Topic: NHLBI
DESCRIPTION (provided by applicant): Informed consent has become an essential component of the doctor-patient interaction. The informed consent process requires that patients not only be given information about proposed medical treatment, but that it be presented in an understandable way so the patient can make meaningful choices about medical alternatives. At the heart of the informed consent doc ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: iXpressGenes, Inc. Topic: 100
Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health